The order intake for ADDvise Group during Q1 2020 amounted to MSEK 137.3 corresponding to an increase of 63 % - Regulatory information

06-04-2020   Regulatory press release

ADDvise Group’s total order intake during the first quarter 2020 amounted to MSEK 137.3 corresponding to an increase of 63 per cent compared with the same period last year. The order intake for the same period last year amounted to MSEK 84.4. 37 per cent of the increase in order intake is due to organic growth. In addition, it is a significant increase compared to the preliminary order intake that was published through the press release dated 24 March 2020. The strong order intake is partly due to the intensified use of medical equipment and consumables due to the outbreak of COVID-19. 

The result of the first quarter will be negatively affected, materially. This is due to interruptions in the supply chain and ADDvise Group personnel, because of absence due to illness. 
 
-    The order intake during the first quarter is an all-time high. Unfortunately, during this present market conditions we do not have the ability to turn the order intake into revenue to the extent desired, said Rikard Akhtarzand, CEO, commenting the order intake. 

 

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 6 April 2020 at 09:50 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com. 
 

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…